{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T17:21:09Z","timestamp":1758475269012},"reference-count":86,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2005,5,3]],"date-time":"2005-05-03T00:00:00Z","timestamp":1115078400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Human Psychopharmacology"],"published-print":{"date-parts":[[2005,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>An Erratum has been published for this article in <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www3.interscience.wiley.com\/cgi-bin\/abstract\/110549216\/ABSTRACT\"> Human Psychopharmacology 20(5), 2005, 375.<\/jats:ext-link><\/jats:p><jats:p>The use of at least one mood\u2010stabilizing agent is common clinical practice in the treatment of bipolar disorder, regardless of the treatment setting or disease phase. However, a consensus definition of \u2018mood stabilizer\u2019 remains to be established. A mood stabilizer has been operationally described as an agent that is useful in at least one phase of bipolar disorder while not worsening any other phase of the illness. More stringent definitions have been proposed, and it can be argued that a clinically effective mood stabilizer would have efficacy in a broad range of affective, psychotic, behavioral and cognitive domains in all phases of bipolar disorder and would be well tolerated across a range of doses for sustained periods. Clinically effective mood stabilizers should treat mania and depression, while preventing recurrence and improving quality of life. Effective treatment should not precipitate mania, depression, or rapid cycling, and should minimize the burden of treatment\u2010emergent side effects. Data from clinical studies of quetiapine are reviewed in context with the literature discussing traditional and emerging mood stabilizers. Using a liberal definition, the evidence for quetiapine qualifies it as a bimodal mood stabilizer based on its demonstrated effectiveness in the treatment of bipolar mania and depression. Further data suggest that quetiapine has promise across all phases of bipolar disorder with the potential to meet even the most stringent definitions of a mood stabilizer. Copyright \u00a9 2005 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/hup.689","type":"journal-article","created":{"date-parts":[[2005,5,6]],"date-time":"2005-05-06T18:49:25Z","timestamp":1115405365000},"page":"225-236","source":"Crossref","is-referenced-by-count":26,"title":["Mood stabilization in the treatment of bipolar disorder: focus on quetiapine"],"prefix":"10.1002","volume":"20","author":[{"given":"Eduard","family":"Vieta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,5,3]]},"reference":[{"key":"e_1_2_1_2_1","first-page":"1","article-title":"Practice guideline for the treatment of patients with bipolar disorder (revision)","volume":"159","author":"American Psychiatric Association","year":"2002","journal-title":"Am J Psychiatry"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(01)00377-9"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(97)00190-X"},{"key":"e_1_2_1_5_1","volume-title":"Presented at the 157th Annual Meeting of the American Psychiatric Association","author":"Baldassano CF","year":"2004"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.57.5.490"},{"issue":"2","key":"e_1_2_1_7_1","first-page":"77","article-title":"Effects of lithium treatment and its discontinuation on suicidal behavior in bipolar manic\u2010depressive disorders","volume":"60","author":"Baldessarini RJ","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_1_8_1","first-page":"167","article-title":"Treatment of bipolar disorder","volume":"1","author":"Bowden C","year":"1997","journal-title":"Curr Rev Mood Anxiety Disord"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(98)00160-8"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1994.03510360044034"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.57.5.481"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.60.4.392"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200427030-00002"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n0116"},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-5618.2002.02229.x"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v60n0203"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.162.7.1351"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(98)00161-X"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-977X(03)00079-8"},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199308000-00009"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2004.00136.x"},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.166.3.378"},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200210000-00011"},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v58n1102"},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1974.01760080077013"},{"key":"e_1_2_1_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200015030-00001"},{"key":"e_1_2_1_27_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.149.1.108"},{"key":"e_1_2_1_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(97)00160-2"},{"issue":"8","key":"e_1_2_1_29_1","first-page":"31","article-title":"Review of quetiapine side effects","volume":"61","author":"Garver DL","year":"2000","journal-title":"J Clin Psychiatry"},{"issue":"14","key":"e_1_2_1_30_1","first-page":"33","article-title":"New treatments for bipolar disorder: the role of atypical neuroleptic agents","volume":"61","author":"Ghaemi SN","year":"2000","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"e_1_2_1_31_1","first-page":"S110","article-title":"Quetiapine treatment of rapid\u2010cycling bipolar disorder: an open prospective study","volume":"5","author":"Ghaemi S","year":"2002","journal-title":"Int J Neuropsychopharmacol"},{"key":"e_1_2_1_32_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.290.11.1467"},{"key":"e_1_2_1_33_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881103017002003"},{"key":"e_1_2_1_34_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1399-5618.2003.00072.x"},{"key":"e_1_2_1_35_1","doi-asserted-by":"publisher","DOI":"10.3109\/15622970209150612"},{"key":"e_1_2_1_36_1","doi-asserted-by":"publisher","DOI":"10.3109\/15622970309167904"},{"key":"e_1_2_1_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300190"},{"key":"e_1_2_1_38_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1399-5618.2003.00069.x"},{"key":"e_1_2_1_39_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n1214"},{"key":"e_1_2_1_40_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n0111"},{"key":"e_1_2_1_41_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.3.4.417"},{"key":"e_1_2_1_42_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.9.1651"},{"key":"e_1_2_1_43_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.4.741"},{"key":"e_1_2_1_44_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199604001-00003"},{"key":"e_1_2_1_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(01)00355-X"},{"key":"e_1_2_1_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mp.4001013"},{"key":"e_1_2_1_47_1","first-page":"1","article-title":"The Expert Consensus Guideline Series. Treatment of bipolar disorder","author":"Keck PE","year":"2004","journal-title":"Postgrad Med Special Report"},{"key":"e_1_2_1_48_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v63n0210"},{"issue":"1","key":"e_1_2_1_49_1","first-page":"60","article-title":"Risperidone monotherapy in acute bipolar mania (abstract P108)","volume":"5","author":"Khanna S","year":"2003","journal-title":"Bipolar Disord"},{"key":"e_1_2_1_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2001.00389.x"},{"issue":"2","key":"e_1_2_1_51_1","first-page":"S157","article-title":"Anti\u2010anxiety effects analysis of quetiapine in bipolar depression","volume":"7","author":"Macfadden W","year":"2004","journal-title":"Int J Neuropsychopharmacol"},{"key":"e_1_2_1_52_1","doi-asserted-by":"publisher","DOI":"10.1177\/026988110001400312"},{"key":"e_1_2_1_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003196"},{"key":"e_1_2_1_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(00)00961-6"},{"key":"e_1_2_1_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2005.02.006"},{"key":"e_1_2_1_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(00)89080-3"},{"key":"e_1_2_1_57_1","unstructured":"Novartis Pharmaceuticals Corporation.2002.Tegretol\u00ae (carbamazepine USP) prescribing information."},{"key":"e_1_2_1_58_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1991.01810250064008"},{"key":"e_1_2_1_59_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-5618.2003.00051.x"},{"key":"e_1_2_1_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-3223(95)00379-7"},{"key":"e_1_2_1_61_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199604001-00005"},{"key":"e_1_2_1_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2004.00115.x"},{"key":"e_1_2_1_63_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.159.7.1146"},{"key":"e_1_2_1_64_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v62n0911"},{"key":"e_1_2_1_65_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v63n1211"},{"key":"e_1_2_1_66_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1997.01830180067009"},{"key":"e_1_2_1_67_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1997.01830130041008"},{"key":"e_1_2_1_68_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.59.1.62"},{"key":"e_1_2_1_69_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.184.4.337"},{"key":"e_1_2_1_70_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.157.2.220"},{"key":"e_1_2_1_71_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.57.9.841"},{"key":"e_1_2_1_72_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.7.1263"},{"key":"e_1_2_1_73_1","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1176\/ajp.156.5.702","article-title":"Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group","volume":"156","author":"Tohen M","year":"1999","journal-title":"Am J Psychiatry"},{"key":"e_1_2_1_74_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.60.11.1079"},{"key":"e_1_2_1_75_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.178.41.s184"},{"key":"e_1_2_1_76_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-5618.4.s1.24.x"},{"issue":"423","key":"e_1_2_1_77_1","first-page":"41","article-title":"Quetiapine for the treatment of rapid\u2010cycling bipolar depression","volume":"110","author":"Vieta E","year":"2004","journal-title":"Acta Psychiatr Scand"},{"key":"e_1_2_1_78_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-5618.2002.01204.x"},{"key":"e_1_2_1_79_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079905X46340"},{"key":"e_1_2_1_80_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.157.2.179"},{"key":"e_1_2_1_81_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-5618.2000.020408.x"},{"key":"e_1_2_1_82_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n0405"},{"key":"e_1_2_1_83_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.324.7332.250"},{"key":"e_1_2_1_84_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.182.2.141"},{"key":"e_1_2_1_85_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000144887.66319.2f"},{"issue":"8","key":"e_1_2_1_86_1","first-page":"52","article-title":"Antipsychotic drug side effect issues in bipolar manic patients","volume":"61","author":"Zarate CA","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_1_87_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v61n0307"}],"container-title":["Human Psychopharmacology: Clinical and Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhup.689","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hup.689","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T01:21:46Z","timestamp":1700184106000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hup.689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5,3]]},"references-count":86,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["10.1002\/hup.689"],"URL":"https:\/\/doi.org\/10.1002\/hup.689","archive":["Portico"],"relation":{},"ISSN":["0885-6222","1099-1077"],"issn-type":[{"value":"0885-6222","type":"print"},{"value":"1099-1077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,5,3]]}}}